Renaissance Technologies’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,245,180
| Closed | -$2.84M | – | 3984 |
|
|
2024
Q2 | $2.84M | Buy |
1,245,180
+341,480
| +38% | +$1.3M | ﹤0.01% | 1654 |
|
|
2024
Q1 | $3.9M | Buy |
903,700
+273,300
| +43% | +$952K | 0.01% | 1574 |
|
|
2023
Q4 | $1.92M | Buy |
630,400
+156,320
| +33% | +$294K | ﹤0.01% | 1971 |
|
|
2023
Q3 | $683K | Sell |
474,080
-97,711
| -17% | -$189K | ﹤0.01% | 2555 |
|
|
2023
Q2 | $1.42M | Buy |
571,791
+128,816
| +29% | +$352K | ﹤0.01% | 2218 |
|
|
2023
Q1 | $1.19M | Sell |
442,975
-204,125
| -32% | -$981K | ﹤0.01% | 2362 |
|
|
2022
Q4 | $3.51M | Buy |
647,100
+544,700
| +532% | +$4.56M | ﹤0.01% | 1720 |
|
|
2022
Q3 | $1.28M | Sell |
102,400
-361,600
| -78% | -$4.13M | ﹤0.01% | 2349 |
|
|
2022
Q2 | $2.29M | Buy |
+464,000
| New | +$2.57M | ﹤0.01% | 2091 |
|
|
2021
Q2 | – | Sell |
-106,100
| Closed | -$2.55M | – | 3850 |
|
|
2021
Q1 | $2.55M | Buy |
+106,100
| New | +$2.47M | ﹤0.01% | 2061 |
|
|
2019
Q2 | – | Sell |
-70,700
| Closed | -$1.17M | – | 3798 |
|
|
2019
Q1 | $1.17M | Buy |
+70,700
| New | +$1.34M | ﹤0.01% | 2599 |
|
|
2018
Q4 | – | Sell |
-11,400
| Closed | -$596K | – | 3675 |
|
|
2018
Q3 | $596K | Buy |
+11,400
| New | +$622K | ﹤0.01% | 2792 |
|
|
2018
Q2 | – | Sell |
-32,000
| Closed | -$1.19M | – | 3595 |
|
|
2018
Q1 | $1.19M | Buy |
+32,000
| New | +$854K | ﹤0.01% | 2588 |
|
Renaissance Technologies's GTHX Position: Q3 2024 in Review
Renaissance Technologies sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 1,245,180 shares — an estimated $2.84M sold.
Renaissance Technologies first reported a position in GTHX in Q1 2018 and held it in 13 quarters. The position peaked at $3.9M in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Renaissance Technologies reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Renaissance Technologies sold 1,245,180 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $2.84M.
- Renaissance Technologies first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
- Renaissance Technologies's G1 Therapeutics, Inc. Common Stock position peaked at $3.9M in Q1 2024.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.